# Study of Immunotherapy to Treat Advanced Prostate Cancer

> **NCT00861614** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 988 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00861614
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2012-11
- **Final completion:** 2015-08
- **Target enrollment:** 988 (ACTUAL)
- **Last updated:** 2016-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861614, "Study of Immunotherapy to Treat Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00861614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*